Cellectis (CLLS) Competitors $2.67 -0.14 (-4.98%) Closing price 04:00 PM EasternExtended Trading$2.64 -0.03 (-1.27%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. TBPH, SAGE, PRME, RZLT, UPXI, SLDB, KURA, ORKA, TERN, and OPTShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Prime Medicine (PRME), Rezolute (RZLT), Upexi (UPXI), Solid Biosciences (SLDB), Kura Oncology (KURA), Oruka Therapeutics (ORKA), Terns Pharmaceuticals (TERN), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Theravance Biopharma Sage Therapeutics Prime Medicine Rezolute Upexi Solid Biosciences Kura Oncology Oruka Therapeutics Terns Pharmaceuticals Opthea Theravance Biopharma (NASDAQ:TBPH) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Which has more volatility & risk, TBPH or CLLS? Theravance Biopharma has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Do institutionals & insiders have more ownership in TBPH or CLLS? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TBPH or CLLS more profitable? Theravance Biopharma has a net margin of -89.38% compared to Cellectis' net margin of -114.82%. Theravance Biopharma's return on equity of -32.37% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-89.38% -32.37% -16.48% Cellectis -114.82%-62.55%-21.19% Do analysts rate TBPH or CLLS? Theravance Biopharma presently has a consensus target price of $16.60, suggesting a potential upside of 50.10%. Cellectis has a consensus target price of $4.00, suggesting a potential upside of 49.31%. Given Theravance Biopharma's higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, TBPH or CLLS? Cellectis has lower revenue, but higher earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M8.59-$56.42M-$1.18-9.37Cellectis$49.22M3.03-$36.76M-$0.86-3.12 Does the media prefer TBPH or CLLS? In the previous week, Cellectis had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for Cellectis and 3 mentions for Theravance Biopharma. Cellectis' average media sentiment score of 0.71 beat Theravance Biopharma's score of 0.47 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTheravance Biopharma beats Cellectis on 9 of the 17 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$148.90M$3.04B$5.59B$9.53BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-3.1221.2227.9619.93Price / Sales3.03200.39389.5465.88Price / CashN/A42.5736.3258.75Price / Book1.148.268.375.77Net Income-$36.76M-$55.06M$3.25B$259.10M7 Day Performance14.98%-3.99%-2.50%-3.41%1 Month Performance75.67%13.86%7.98%8.53%1 Year Performance22.89%4.02%34.65%15.75% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis2.8838 of 5 stars$2.67-5.0%$4.00+49.8%+27.1%$148.40M$49.22M-3.10290News CoverageUpcoming EarningsTBPHTheravance Biopharma1.7343 of 5 stars$11.06+0.3%$16.60+50.1%+9.1%$551.52M$64.38M0.00110Upcoming EarningsSAGESage Therapeutics3.4056 of 5 stars$8.78-0.2%$8.02-8.7%-19.5%$551.06M$41.24M0.00690Positive NewsPRMEPrime Medicine3.8423 of 5 stars$4.09-2.9%$9.25+126.2%-31.2%$550.09M$3.85M-2.00234News CoverageRZLTRezolute2.3362 of 5 stars$6.38+1.3%$11.83+85.5%+35.1%$548.08MN/A0.0040Analyst RevisionUPXIUpexi2.6983 of 5 stars$5.88-3.8%$16.00+172.1%-24.6%$546M$26M0.00130News CoveragePositive NewsOptions VolumeGap DownSLDBSolid Biosciences3.2939 of 5 stars$7.02+0.3%$15.10+115.1%-25.6%$542.61M$8.09M0.00100KURAKura Oncology4.5141 of 5 stars$6.20-0.5%$24.50+295.2%-69.5%$539.36M$53.88M0.00130Positive NewsUpcoming EarningsORKAOruka Therapeutics2.7026 of 5 stars$14.01-1.7%$40.38+188.2%N/A$533.53MN/A0.00N/ATERNTerns Pharmaceuticals3.7629 of 5 stars$5.95-1.7%$15.63+162.6%-31.0%$528.39MN/A0.0040Upcoming EarningsOPTOpthea0.3553 of 5 stars$3.41+7.2%$1.33-60.9%+51.6%$524.84M$120K0.008Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies TBPH Alternatives SAGE Alternatives PRME Alternatives RZLT Alternatives UPXI Alternatives SLDB Alternatives KURA Alternatives ORKA Alternatives TERN Alternatives OPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
